Equities research analysts expect Cronos Group Inc (NASDAQ:CRON) to post earnings per share of ($0.03) for the current quarter, according to Zacks. Four analysts have issued estimates for Cronos Group’s earnings, with the highest EPS estimate coming in at $0.00 and the lowest estimate coming in at ($0.06). Cronos Group also posted earnings of ($0.03) per share in the same quarter last year. The firm is expected to issue its next quarterly earnings results on Tuesday, November 12th.
According to Zacks, analysts expect that Cronos Group will report full year earnings of ($0.07) per share for the current year, with EPS estimates ranging from ($0.10) to ($0.05). For the next year, analysts expect that the business will post earnings of ($0.09) per share, with EPS estimates ranging from ($0.32) to $0.04. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Cronos Group.
Cronos Group (NASDAQ:CRON) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Cronos Group had a return on equity of 60.20% and a net margin of 2,521.25%. The firm had revenue of $10.80 million for the quarter, compared to analysts’ expectations of $7.16 million. The firm’s quarterly revenue was up 217.6% on a year-over-year basis.
Several equities research analysts have recently weighed in on CRON shares. Stifel Nicolaus started coverage on Cronos Group in a research report on Wednesday, June 5th. They set a “hold” rating on the stock. Zacks Investment Research cut Cronos Group from a “buy” rating to a “hold” rating in a research report on Monday, August 12th. Consumer Edge started coverage on Cronos Group in a research report on Friday, June 28th. They set an “equal weight” rating on the stock. ValuEngine cut Cronos Group from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, BMO Capital Markets upgraded Cronos Group from an “underperform” rating to a “market perform” rating in a research report on Thursday, September 5th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $19.62.
Several hedge funds have recently bought and sold shares of the stock. Captrust Financial Advisors grew its position in Cronos Group by 7,925.0% during the second quarter. Captrust Financial Advisors now owns 1,605 shares of the company’s stock valued at $26,000 after acquiring an additional 1,585 shares during the last quarter. Commonwealth Bank of Australia bought a new position in Cronos Group during the second quarter valued at approximately $29,000. Focused Wealth Management Inc grew its position in Cronos Group by 48.5% during the first quarter. Focused Wealth Management Inc now owns 1,849 shares of the company’s stock valued at $34,000 after acquiring an additional 604 shares during the last quarter. US Bancorp DE grew its position in Cronos Group by 90.9% during the second quarter. US Bancorp DE now owns 2,100 shares of the company’s stock valued at $34,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Joseph P. Lucia & Associates LLC bought a new position in Cronos Group during the second quarter valued at approximately $35,000. Institutional investors own 11.63% of the company’s stock.
Shares of CRON traded down $0.24 during midday trading on Wednesday, hitting $10.91. 145,844 shares of the company traded hands, compared to its average volume of 3,296,257. The stock has a 50-day moving average of $12.25 and a 200-day moving average of $15.74. Cronos Group has a one year low of $6.50 and a one year high of $25.10. The firm has a market cap of $3.93 billion, a P/E ratio of -136.25 and a beta of 3.55.
Cronos Group Company Profile
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada.
See Also: What is channel trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.